Interferon Toxicities in Melanoma Treatment
NCT02794636
·
clinicaltrials.gov ↗
COMPLETED
Status
436
Enrollment
INDUSTRY
Sponsor class
Conditions
Stage III Melanoma
Sponsor
Bristol-Myers Squibb